Summary Two policies of palliative thoracic radiotherapy for NSCLC have been compared in a randomised multicentre controlled trial aimed at simplifying the palliative treatment of patients with poor performance status. A total of 235 patients were entered. They had inoperable, microscopically confirmed disease, too advanced for 'curative' radiotherapy. Their main symptoms were related to the primary intrathoracic tumour even if metastases were present, and they had a poor performance status. Patients were allocated at random to regimens of either 17 Gy given in two fractions of 8.5 Gy 1 week apart (F2 regimen, 117 patients), or a single fraction of 10 Gy (Fl regimen, 118 patients). Two patients (one in each group) were excluded from all analyses because they were found to have had previously treated malignant disease and had been admitted in error. On admission, 95% of the 233 eligible patients had cough, 47% haemoptysis, 59% chest pain, 64% anorexia, and 16% dysphagia. As assessed by the clinicians, these symptoms were palliated in high proportions of patients, ranging in the F2 group from 48% for cough to 75% for haemoptysis, and in the Fl group from 55% for anorexia to 72% for haemoptysis and chest pain. For all five symptoms the median duration of palliation was 50% or more of survival. All these results were similar in the two treatment groups. In contrast, on daily assessment by the patients using a diary card, those treated with the F2 regimen experienced substantially more dysphagia, which was recorded in 56% of the patients compared with 23% in the Fl group (difference 33%: 95% confidence interval 17-48%). The median survival from randomisation was 100 days in the F2 group and 122 days in the Fl group. The Fl regimen, as it requires only a single attendance for treatment, is recommended as a palliative regimen for patients with inoperable NSCLC and a poor performance status.
The majority of patients with inoperable NSCLC have tumour already too advanced for radical radiotherapy at the time they present, but require palliative treatment for major symptoms related to intrathoracic tumour (Carrol et al., 1986) . It is usual to treat such patients, either at first presentation or when significant symptoms develop, with a course of palliative radiotherapy (Mulshine et al., 1986 ).
An earlier randomised clinical trial (MRC Lung Cancer Working Party, 1991) showed that in the management of patients with previously untreated, inoperable NSCLC too advanced for 'curative' or long-term palliative radiotherapy, effective palliation of chest symptoms was achieved with only two fractions of 8.5 Gy given 1 week apart (total dose 17 Gy). This regimen was as effective as a regimen considered to be conventional treatment at the time, namely a multifractionated regimen of 30 Gy in ten equal fractions (or the biologically equivalent dose of 27 Gy in six equal fractions) given daily except at weekends. The main symptoms, namely cough, haemoptysis, chest pain, and anorexia, were palliated in high and similar proportions of patients in the two treatment groups, and the main adverse effect of the radiotherapy, namely dysphagia, was of similar frequency and severity as recorded daily by the patients themselves using a diary card. Performance status on admission had a major prognostic effect, but there was no difference in survival between the two randomised groups. The two-fraction regimen was therefore recommended as it required patients to The aim of the present study was to investigate whether only a single fraction of radiotherapy could provide equally good palliation as the two-fraction regimen used in the previous study, in the management of patients with inoperable NSCLC, a poor performance status, and whose main symptoms were related to intrathoracic tumour. A survival difference was not anticipated. In a study of purely palliative radiotherapy, the intake was restricted to patients with a poor performance status, because performance status on admission was known to affect the duration of survival. In patients with a better status a higher-dose regimen aimed not only at palliation but also at prolonging survival might be preferred.
Methods

Eligibility
Patients of either sex and any age were eligible for the trial if they had previously untreated, inoperable, histologically or cytologically proved lung carcinoma of any histological type except small-cell. It was required that their disease was considered too advanced for 'curative' or long-term palliative radiotherapy, but that survival was anticipated to exceed 2 months from admission. They had to have poor performance status, namely WHO grade 2-4 (World Health Organization, 1979) , and their main symptoms related to the primary intrathoracic tumour, even if metastases were present. Local ethics committee approval of the protocol and individual patient consent were required.
The diagnoses were made by the histopathologists from the referring centres according to the WHO classification (World Health Organization, 1981) . To obtain uniformity of classification, the slides were later examined by a single reference histopathologist. Daily assessment by patients For their first 6 months in the study, the patients completed an MRC patient diary card (Fayers et al., 1991) every evening after their last meal, recording how they had been feeling during the previous 24 h using a numerical code (Figure 1 ). 
(1 1) mild to none, from moderate to mild or none, or from severe to moderate, mild, or none), at one or more assessment. Duration of palliation is expressed (i) as the median duration of palliation and (ii) as the percentage of patient survival time during which there was palliation. The variation in these two statistics is expressed by the interquartile range (Q), which is the range of the two middle quarters of the results. Ninety-five per cent confidence intervals (CI) for proportions are given where appropriate. The Kaplan-Meier estimate was used to calculate survival curves and a log-rank procedure was used to calculate confidence intervals for the observed differences. The effect of factors for prognosis on survival was assessed by a proportional hazards regression model as described by Altman (1991) . The trial data were managed using the COMPACT program (COMPACT Steering Committee, 1991 Of the 233 patients, 79% were male ( Two centres mentioned that a few of their patients had complained of chest pain for 1 day immediately following a dose of radiotherapy, but this was not formally recorded.
Radiation myelopathy occurred in one patient (F2). Seventeen months after her allocated radiotherapy she presented with altered sensation in her legs, numbness and weakness in her left leg and bilateral upgoing plantar responses. She had a sensory level at T8. She died 1 year later. At autopsy there was no invasion of the spinal cord by tumour. There were scattered areas of necrosis in the white matter confined to the irradiated segments (TI to T8), and the blood vessels within this section showed marked hyaline fibrosis in their walls. Areas of coagulative necrosis with calcium deposition were also seen. These findings were considered to confirm a diagnosis of radiation myelopathy. Survivalfrom allocation The status of all 233 eligible patients is known for at least 2 years from randomisation. As anticipated, there was no appreciable difference in survival between the two treatment groups (Figure 4) In the present trial, which differed from the first in that it was confined to patients with a poor performance status, the two-fraction regimen was used as the standard and was compared in a prospective randomised trial with a regimen of a single fraction of 10 Gy. The aim was to simplify palliative treatment even further, particularly in the management of 12 la 24
Months from randomisation (Ganz et al., 1988; Geddes et al., 1990 We are comparing such assessments in more detail in current trials in which patients are completing Rotterdam symptom check lists (de Haes et al., 1986) and hospital anxiety and depression scales (Zigmond & Snaith, 1983) There is concern among some radiotherapists about the potential immediate adverse effects of large single fractions as in the single-fraction 10 Gy regimen (Macbeth & Bolger, 1991 In conclusion, the present trial and the previous trial (MRC Lung Cancer Working Party, 1991) have provided two useful radiotherapy regimens that give high levels of palliation of the major chest symptoms for at least half of the remaining survival time in high proportions of patients with inoperable NSCLC. The single-fraction regimen has the advantage that, unlike the two-fraction regimen, it causes little if any dysphagia. It involves only a single attendance for treatment and should prove to be of great value in the palliative treatment of patients with a poor prognosis.
